RJFSA
LEXX icon

Raymond James Financial Services Advisors’s Lexaria Bioscience LEXX Stock Holding History

Raymond James Financial Services Advisors’s Portfolio LEXX Stock Details LEXX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		$137K Sell
2,993
-260
-8% -$12.4K ﹤0.01% 3249
2024
Q2 		$136K Buy
3,253
+616
+23% +$27.7K ﹤0.01% 3192
2024
Q1 		$144K Buy
+2,637
New +$101K ﹤0.01% 3165

Other funds holding LEXX

ICM
Invenomic Capital Management Boston, Massachusetts $1.67B AUM 1.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
G
GenTrust Miami, Florida $2.6B AUM 18.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
WG
Welch Group Birmingham, Alabama $2.93B AUM 27.62% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Raymond James Financial Services Advisors's LEXX Position: Q3 2024 in Review

Raymond James Financial Services Advisors reduced its Lexaria Bioscience (LEXX) stake by 8% in Q3 2024, selling an estimated $12.4K and leaving 2,993 shares worth $137K. The position accounts for ﹤0.01% of the portfolio, ranked #3249.

Raymond James Financial Services Advisors first reported a position in LEXX in Q1 2024 and has held it in 3 quarters since. The position peaked at $144K in Q1 2024. 27 funds tracked by Wall St. Rank hold LEXX as of Q3 2024.

  • Raymond James Financial Services Advisors held 2,993 shares of Lexaria Bioscience worth $137K as of Q3 2024.
  • Raymond James Financial Services Advisors sold 260 Lexaria Bioscience shares in Q3 2024, an estimated $12.4K.
  • Lexaria Bioscience made up ﹤0.01% of Raymond James Financial Services Advisors's portfolio in Q3 2024, its #3249 holding.
  • Raymond James Financial Services Advisors first reported a position in Lexaria Bioscience in Q1 2024 and has held it in 3 quarters since.
  • Raymond James Financial Services Advisors's Lexaria Bioscience position peaked at $144K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Lexaria Bioscience as of Q3 2024.

Based on Raymond James Financial Services Advisors's 13F filing for Q3 2024, filed 18 Oct 2024.